SCHEMBL3429291

SCHEMBL3429291

Nc1ncnc2c1ncn2[C@@H]1O[C@H](COC(=O)CCCC(=O)O)[C@@H](O)[C@H]1O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 1/20 0.69
PRKACA P17612 2/20 0.68
P2RY1 P47900 4/20 0.64
ADORA1 P30542 3/20 0.64
P2RY2 P41231 3/20 0.64
SMN1; SMN2 Q16637 3/20 0.64
SRC P12931 2/20 0.64
DNPH1 O43598 1/20 0.64
PRKAB2 O43741 1/20 0.64
TRPM2 O94759 1/20 0.64
LDHA P00338 1/20 0.64
ADRB2 P07550 1/20 0.64
FBP1 P09467 1/20 0.64
PRKAG1 P54619 1/20 0.64
PRKAA2 P54646 1/20 0.64
PDE4D Q08499 1/20 0.64
KCNH2 Q12809 1/20 0.64
PRKAA1 Q13131 1/20 0.64
PDE3A Q14432 1/20 0.64
TAS1R3 Q7RTX0 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16945766 1.00 PLA2G2A (0.69) PLA2G2APRKACAP2RY1ADORA1P2RY2
SCHEMBL15297005 0.94 PLA2G2A (0.68) PLA2G2APRKACAP2RY1ADORA1P2RY2
SCHEMBL2790606 0.94 PLA2G2A (0.68) PLA2G2APRKACAP2RY1ADORA1P2RY2
SCHEMBL16945765 0.94 PLA2G2A (0.68) PLA2G2APRKACAP2RY1ADORA1P2RY2
SCHEMBL14178285 0.94 PLA2G2A (0.68) PLA2G2APRKACAP2RY1ADORA1P2RY2
Adenosine SCHEMBL8577634 0.91 ADORA3 (0.71) PLA2G2APRKACAP2RY1ADORA1P2RY2
SCHEMBL10585105 0.91 EHMT1 (0.69) PRKACAP2RY1ADORA1P2RY2SMN1; SMN2
SCHEMBL10587627 0.90 EHMT1 (0.71) PRKACAP2RY1ADORA1P2RY2SMN1; SMN2
SCHEMBL5561909 0.89 EHMT1 (0.69) PRKACAP2RY1ADORA1P2RY2SMN1; SMN2
SCHEMBL1669299 0.89 EHMT1 (0.69) PRKACAP2RY1ADORA1P2RY2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2204154-B1 Association of monosaccharides and adenosine and its cosmetic use ORÉAL L (FR) 2016-10-12 EP disclosed
EP-2471803-B1 Compounds that interact with kinases ALCHEMIA LTD (AU) 2013-11-27 EP disclosed
EP-2204154-A1 Association of monosaccharides and adenosine and its cosmetic use L'OREAL (FR) 2010-07-07 EP disclosed
US-20100168049-A1 COMBINATION OF MONOSACCHARIDES AND ADENOSINE AND USE THEREOF L'OREAL (FR) 2010-07-01 US disclosed
EP-1878470-B1 Skin depigmentation method OREAL (FR) 2009-03-11 EP disclosed
EP-1878470-A1 Skin depigmentation method L'Oréal (FR) 2008-01-16 EP disclosed
US-20070258921-A1 PROCESS FOR DEPIGMENTING THE SKIN L'OREAL (FR) 2007-11-08 US disclosed
EP-1847547-A1 Anti-wrinkle cosmetic composition L'Oréal (FR) 2007-10-24 EP disclosed
US-20070237734-A1 ANTI-WRINKLE COSMETIC COMPOSITION L'OREAL (FR) 2007-10-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070258921-A1 PROCESS FOR DEPIGMENTING THE SKIN TYR, CUTA, NQO1 PLA2G2A 1478/4885PRKACA 249/4885P2RY1 4495/4885
US-20070237734-A1 ANTI-WRINKLE COSMETIC COMPOSITION ADORA2A, ADORA3, ADORA1 PLA2G2A 81/4885PRKACA 380/4885P2RY1 93/4885
US-20100168049-A1 COMBINATION OF MONOSACCHARIDES AND ADENOSINE AND USE THEREOF ADORA2A, ADORA1, ADORA3 PLA2G2A 858/4885PRKACA 119/4885P2RY1 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.